Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,

Abstract: The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating synucleinopathies, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).

Abstract: The present invention relates to a composition comprising at least one mimotope of an epitope of alpha-synuclein for use in a method for preventing and/or treating ?-amyloidoses including Alzheimer's disease, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and Haemophilus influenzae protein D (protein D).

Abstract: A mobile apparatus and a process for adequately irrigating soil, wherein the apparatus has an irrigation unit for irrigating soil and a mobile microwave measurement unit for determining the water content of the soil along a measurement path. A control unit is used to irrigate the soil along the measurement path depending on the measured water content. The apparatus preferably also has a water tank and leaves an area of soil to be irrigated autonomously.

Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150,

Abstract: The invention relates to a method for the automatic irrigation of plants, wherein the temporal progression of soil moisture is determined from measured soil moisture values, and said progression is used for the calculation of an optimized irrigation time duration, such that both water excess in the soil and soil drying are avoided as much as possible. Preferably, the time duration of irrigation is constantly evaluated and optimized using comparisons of measured values with prespecified moisture- and dryness threshold values (GWmoist, GWdry), and automatically adjusted to changing environmental conditions and/or plant requirements.

Abstract: A method for the automatic irrigation of plants, wherein the temporal progression of soil moisture is determined from measured soil moisture values, and said progression is used for the calculation of an optimized irrigation time duration, such that both water excess in the soil and soil drying are avoided as much as possible. Preferably, the time duration of irrigation is constantly evaluated and optimized using comparisons of measured values with prespecified moisture- and dryness threshold values (GWmoist, GWdry), and automatically adjusted to changing environmental conditions and/or plant requirements.

Abstract: A tibial implant system has an ultra-high molecular weight polyethylene tibial insert which can engage with either one of two tibial trays through differing means of engagement. The tibial insert includes a locking wire and locking tab disposed along an anterior surface and a locking recess disposed along a posterior surface. A first polymeric tibial tray includes a bead along an anterior wall and an undercut area along a posterior wall. A second metallic tibial tray includes a plurality of barbs along an anterior wall and an undercut area along a posterior wall.

Abstract: Vaccine comprising a peptide bound to a pharmaceutically acceptable carrier, said peptide having the amino acid sequence (SEQ?ID?NO:?1) (X1)m?(X2)n?(X3)o?X4?X5?H?P?X6 (Formula?I), for treating and/or preventing a physical disorder associated with the renin-activated angiotensin system, wherein X1 is G or D, X2 is A, P, M, G, or R, X3 is G, A, H, or V, X4 is S, A, D, or Y, X5 is A, D, H, S, N, or I, X6 is A, L or F, wherein m, n and o are independently 0 or 1 under the premise that when o is 0 m and n are 0 and when n is 0 m is 0, and wherein the peptide is not DRVYIHPF (SEQ ID NO:4).

Abstract: Disclosed is a method for diagnosing Alzheimer's disease (AD) wherein A?-specific antibodies in a biological sample of a person that is suspected of having AD are detected comprising the following steps: —contacting the sample with A?-aggregates or with particles having A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and —detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); and wherein the amount of A?-specific antibodies detected is compared with the amount in a sample of known AD status.

Abstract: Disclosed is a method for detecting A?-specific antibodies in a biological sample comprising the following steps:—contacting the sample with A?-aggregates or with particles comprising A?-aggregate like surfaces and allowing the A?-specific antibodies to bind to the A?-aggregates, and -detecting the A?-specific antibodies bound to the A?-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting FACS.

Abstract: The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.

Abstract: A wheel suspension for motor vehicles includes at least one wheel guide element which is articulated both on an auxiliary frame that can be connected to the body of the motor vehicle and on a wheel carrier, a suspension and damping system as well as a steering system for the wheel. To achieve a universally applicable wheel suspension using identical parts, the auxiliary frame for each wheel suspension is designed as an independent modular frame, on which the a wheel guide element(s) is/are articulated, on which the suspension and damping system is supported, and on which at least one actuator is arranged directly or indirectly for actuating the suspension and damping system and/or the steering system and thus for setting predetermined wheel-specific wheel guidance and/or steering parameters.

Abstract: The present invention relates to a method for treating atherosclerosis and/or atherosclerosis sequelae with a compound that includes FX8(F)oPX9HX10X11X12DX2X3X4X5X6X7 where X8 is G, A, F, Y or K, X9 is E, Y, A, Q, K or S, X10 is H, V, L, F or I, X11 is L, W, S, I, F or Y, X12 is V, T, F or I, X5 is S or Y, X6 is L, A or I, X7 is S, N or T, and o is 0 or 1.

Abstract: The invention relates to an arrangement of a stabilizer (44), which is configured in two parts, on a wheel suspension for a motor vehicle, characterized in that the stabilizer parts (43) thereof can be rotated relative to one another in the same or opposite direction by means of an associated motor/gear unit (46). Each stabilizer part (43) comprises a hollow-cylindrical outer torsion bar (49) whose end on the gear side (45) is connected to a gear output (50a) and whose end distal from the gear is connected for drive purposes to an inner torsion bar (47) which is guided through the hollow-cylindrical outer torsion bar (49) and out of the end (45) on the gear side of the hollow-cylindrical outer torsion bar. The inner torsion bar (47) is directly or indirectly connected to an output lever (41) which is articulated on a wheel suspension element (16).

Abstract: A wheel suspension for motor vehicles includes at least one upper control arm, in particular an upper transverse control arm, and at least one lower control arm, in particular a lower transverse control arm, which are hinged on the body of the motor vehicle suspension on the one hand, and on the other hand are connected to a wheel carrier, thus forming a preferred, substantially vertical steering axle. At least one suspension spring and at least one shock absorber are provided. The at least one suspension spring and/or the at least one shock absorber are designed to be rotatable.

Abstract: The present invention relates to a compound comprising a peptide for treating, preventing and/or ameliorating motor symptoms of Parkinson's disease, said peptide having a binding capacity to an antibody which is specific for an epitope of the amyloid-beta-peptide (A?).

Abstract: Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I) wherein any NMP is a 2? deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2? deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 1

Abstract: The invention relates to an arrangement of a stabilizer (26), which is configured in two parts, on a wheel suspension for a motor vehicle, comprising torsion bars (26b) which are separated from each other and are each articulated on wheel suspension elements (16) by means of an output lever (26a) and can be co-rotated in the same or opposite direction by means of associated actuating devices (30), wherein each torsion bar (26b) is extended with a hollow shaft (26e) which encompasses the torsion bar (26b) in order to increase the effective torsion length, the output lever (26a) being formed on the hollow shaft. According to the invention, the torsion bar (26b) is mounted in a fixed bearing (59) in the actuating device (30) and in an axial loose bearing (26d) in the hollow shaft (26e).

Abstract: A motor vehicle has at least one drive unit for generating a drive torque, and has an accelerator pedal which is acted on with a restoring force and which can be adjusted by an actuating travel in order to predefine a setpoint torque. The motor vehicle also has a control device which actuates the drive unit on the basis of the setpoint torque. The control device additionally determines a presently available drive torque, and as a function of the presently available drive torque, varies the characteristic curve of the accelerator pedal, which expresses the restoring force versus the actuating travel of the accelerator pedal.